Zobrazeno 1 - 10
of 86
pro vyhledávání: '"Marshall T. Schreeder"'
Autor:
Sven de Vos, Nina D. Wagner-Johnston, Steven E. Coutre, Ian W. Flinn, Marshall T. Schreeder, Nathan H. Fowler, Jeff P. Sharman, Ralph V. Boccia, Jacqueline C. Barrientos, Kanti R. Rai, Thomas E. Boyd, Richard R. Furman, Yeonhee Kim, Wayne R. Godfrey, John P. Leonard
Publikováno v:
Blood Advances, Vol 1, Iss 2, Pp 122-131 (2016)
Abstract: Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib
Externí odkaz:
https://doaj.org/article/fc19ab6357334e8a83fbb5997926325c
Autor:
Steven E. Coutre, Ian W. Flinn, Sven de Vos, Jacqueline C. Barrientos, Marshall T. Schreeder, Nina D. Wagner-Johnson, Jeff P. Sharman, Thomas E. Boyd, Nathan Fowler, Lyndah Dreiling, Yeonhee Kim, Siddhartha Mitra, Kanti Rai, John P. Leonard, Richard R. Furman
Publikováno v:
HemaSphere, Vol 2, Iss 3 (2018)
Abstract. Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activit
Externí odkaz:
https://doaj.org/article/6da8a4ddda5d45c196dab088c2d15d99
Autor:
Frederick Lansigan, Jeff P. Sharman, Patrick M Travis, Ian W. Flinn, Michael S. Weiss, Kathryn S. Kolibaba, Jason C. Chandler, Stephen J. Schuster, Hari P. Miskin, Suman Kambhampati, Nilanjan Ghosh, Danielle M. Brander, Scott D. Lunin, John M. Burke, Mikhail Shtivelband, Anthony R. Mato, Alexander Zweibach, Peter Sportelli, Marshall T. Schreeder
Publikováno v:
The Lancet Haematology. 8:e254-e266
Summary Background Patients with chronic lymphocytic leukaemia and high-risk features have poorer outcomes on ibrutinib than those without high-risk features. The aim of this study was to assess the benefit of adding ublituximab, an anti-CD20 monoclo
Autor:
Jennifer R. Brown, Wael A. Harb, Brian T. Hill, Janice Gabrilove, Jeff P. Sharman, Marshall T. Schreeder, Paul M. Barr, James M. Foran, Thomas P. Miller, Jan A. Burger, Kevin R. Kelly, Daruka Mahadevan, Shuo Ma, Yan Li, Daniel W. Pierce, Evelyn Barnett, Jeffrey Marine, Monika Miranda, Ada Azaryan, Xujie Yu, Pilar Nava-Parada, Jay Mei, Thomas J. Kipps
Publikováno v:
Haematologica, Vol 101, Iss 7 (2016)
Externí odkaz:
https://doaj.org/article/db5807b237c04ee6a0ab7b5f4796f605
Autor:
Matthew A. Lunning, Hari P. Miskin, Jonathon B. Cohen, Nathan Fowler, Marshall T. Schreeder, Tanya Siddiqi, Loretta J. Nastoupil, Michael S. Weiss, Jan A. Burger, Christopher R. Flowers, Susan O'Brien, Julie M. Vose, Peter Sportelli, William G. Wierda
Publikováno v:
Blood
Targeting both CD20 and phosphatidylinositol 3-kinase (PI3K), a protein that is critically involved in B-cell maturation, could be an efficacious strategy for treating B-cell malignancies. The safety of the next-generation compounds umbralisib, a PI3
Autor:
Marshall T. Schreeder, Julie M. Vose, Matthew A. Lunning, Susan O'Brien, Hari P. Miskin, Loretta J. Nastoupil, Michael S. Weiss, Christopher R. Flowers, William G. Wierda, Jan A. Burger, Jonathon B. Cohen, M. Purdom, Nathan Fowler, Tanya Siddiqi, Peter Sportelli
Publikováno v:
The Lancet Haematology. 6:e100-e109
Summary Background Therapeutic approaches for B-cell malignancies continue to evolve, especially with regard to combination approaches. We assessed the safety and efficacy of the triplet ublituximab, umbralisib, and ibrutinib in patients with advance
Autor:
Ian W. Flinn, Richard R. Furman, Kanti R. Rai, Nina Wagner-Johnson, Nathan Fowler, Lyndah Dreiling, Steven Coutre, Jeff P. Sharman, Yeonhee Kim, John P. Leonard, Sven de Vos, Marshall T. Schreeder, Siddhartha Mitra, Thomas E. Boyd, Jacqueline C. Barrientos
Publikováno v:
HemaSphere
HemaSphere, Vol 2, Iss 3 (2018)
HemaSphere, Vol 2, Iss 3 (2018)
Phosphatidylinositol 3-kinase-delta (PI3Kδ) signaling is critical for proliferation, survival, homing, and tissue retention of malignant B cells. Idelalisib, a selective oral inhibitor of PI3Kδ, has shown considerable single-agent activity in patie
Autor:
Ahmed Sawas, Petros Nikolinakos, Jennifer E Amengual, Daruka Mahadevan, Jill M. Kolesar, Hari P. Miskin, Marshall T. Schreeder, Charles M. Farber, Peter Sportelli, John G. Kuhn, Changchun Deng, Mazen Khalil, Owen A. O'Connor
Publikováno v:
British Journal of Haematology
Summary This phase 1/2 study evaluated the safety, pharmacokinetic behavior and anti‐tumour activity of ublituximab, a unique type I, chimeric, glycoengineered anti‐CD20 monoclonal antibody, in rituximab‐relapsed or ‐refractory patients with
Autor:
Yeonhee Kim, Ian W. Flinn, Richard R. Furman, Nina D. Wagner-Johnston, Nathan Fowler, Thomas E. Boyd, Steven Coutre, Ralph V. Boccia, Sven de Vos, Marshall T. Schreeder, John P. Leonard, Kanti R. Rai, Jacqueline C. Barrientos, Jeff P. Sharman, Wayne R. Godfrey
Publikováno v:
Blood Advances. 1:122-131
Idelalisib, a first-in-class oral inhibitor of phosphatidylinositol-3-kinase δ, has shown considerable antitumor activity as a monotherapy in recurrent indolent non-Hodgkin lymphoma (iNHL). To evaluate the safety and activity of idelalisib in combin
Autor:
Kathryn S. Kolibaba, Jason C. Chandler, Michael S. Weiss, John M. Burke, Hari P. Miskin, Alexander Zweibach, Nilanjan Ghosh, Patrick M. Travis, Frederick Lansigan, Ian W. Flinn, Stephen J. Schuster, Suman Kambhampati, Marshall T. Schreeder, Mikhail Shtivelband, Danielle M. Brander, Anthony R. Mato, Scott D. Lunin, Peter Sportelli, Jeff P. Sharman
Publikováno v:
Journal of Clinical Oncology. 38:8022-8022
8022 Background: The BTK inhibitor ibrutinib (IB) has advanced the treatment for patients (pts) with CLL, however, among pts with high-risk CLL, disease control with IB is less durable. Ublituximab (UTX) is a glycoengineered mAb with enhanced ADCC. T